See the latest news and media coverage for Oblique Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Biotechnology company developing antibody medicines
obliquet.comLast updated
In short: Oblique Therapeutics called an EGM to decide between continued operation and liquidation after equity fell below half its share capital.
The board proposes continued operations because equity is less than half of the share capital, alternatively liquidation with zero kronor per share.
Convertibles of 15.8 MSEK are converted to 10.5 million new A-shares, increasing the number of shares to 56.2 million with 18.77% dilution.
The issue was subscribed to 95.4% of 14.5 MSEK. Convertibles are converted in 2026 to shares with 25.6% dilution.
The addition is approved by the Financial Supervisory Authority due to errors in the conversion rates. Investors can withdraw their subscription until 25 June 2025.
Oblique Therapeutics AB ("Oblique" or the "Company") today announces the outcome of the rights issue that closed on June 30. The rights issue was fully...
The board of directors of Oblique Therapeutics AB (publ) ("Oblique Therapeutics" or "the Company") announces that all convertibles issued within the framework of...
"We have carried out necessary and structural changes to optimize our capital use and at the same time ensure that we fully prioritize what has the greatest value creation...
Oblique Therapeutics has developed a patented technology, AbiProt®, with which one can identify areas on target proteins in the cell membrane where antibodies can bind. Information regarding these...
Track Oblique Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Oblique Therapeutics and other trending companies.